Skip to main content

Table 3 The adverse events in the 40 Chinese patients with mCRC treated with the SOL regimen

From: Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer

Event NCI-CTCAE grade, version 3.0 [cases (%)]
1 2 3
Leukopenia 7 (17.5) 7 (17.5) 0
Neutropenia 6 (15.0) 4 (10.0) 1 (2.5)
Anemia 3 (7.5) 3 (7.5) 0
Thrombocytopenia 5 (12.5) 7 (17.5) 3 (7.5)
Anorexia 19 (47.5) 8 (20.0) 0
Nausea 16 (40.0) 6 (15.0) 3 (7.5)
Vomiting 6 (15.0) 6 (15.0) 3 (7.5)
Diarrhea 5 (12.5) 9 (22.5) 8 (20.0)
Stomatitis 4 (10.0) 2 (5.0) 1 (2.5)
Constipation 4 (10.0) 0 0
Fatigue 18 (45.0) 5 (12.5) 1 (2.5)
Alopecia 29 (72.5) 6 (15.0) 0
Pigmentation 5 (12.5) 14 (35.0) 0
Hand-foot syndrome 14 (35.0) 2 (5.0) 1 (2.5)
Neuropathy 21 (52.5) 12 (30.0) 5 (12.5)
Abnormal ALT/AST 7 (17.5) 3 (7.5) 1 (2.5)
  1. NCI-CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events, ALT/AST alanine transaminase/aspartate transaminase. Other abbreviations as in Tables 1 and 2